Compare RETO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | HSCS |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | China | United States |
| Employees | N/A | 12 |
| Industry | Multi-Sector Companies | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.2M |
| IPO Year | 2016 | N/A |
| Metric | RETO | HSCS |
|---|---|---|
| Price | $0.69 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.0M | 15.3K |
| Earning Date | 05-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $1.89 |
| 52 Week High | $4.66 | $6.47 |
| Indicator | RETO | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 40.26 |
| Support Level | $0.61 | $1.95 |
| Resistance Level | $1.30 | $2.60 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 19.37 | 37.11 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.